Alteogen has secured U.S. patent protection for its enzyme ALT-B4 until 2043, positioning it favorably in the competitive market for subcutaneous (SC) formulation-converting enzymes. Despite speculation about increasing competition from companies like Samsung Bioepis, analysts maintain that Alteogen’s patent and superior enzyme performance distinguish it from others targeting similar markets. Patent disputes have validated its advantages, and securities analysts continue to support Alteogen’s strong market position. CEO Taeyeon Jeon emphasized the company’s commitment to shareholder value amid market scrutiny.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.asiae.co.kr/en/article/2026072018175601778
